Purpose. The efficacy and safety of i.v. alteplase up to 4.5 hours after acute ischemic stroke (AIS) onset were evaluated. Summary. Stroke is the leading cause of disability in the elderly, and i.v.

A noninferiority trial comparing two doses of thrombolytic therapy with the tissue plasminogen activator (tPA) alteplase has failed to demonstrate that low-dose therapy is as effective as ...

Please provide your email address to receive an email when new articles are posted on . At 90 days after minor nondisabling acute ischemic stroke, there was no difference in functional outcomes ...

Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to ...

Thrombolytic therapy with alteplase is widely used for symptomatic PVT, but evidence comparing it directly with tenecteplase ...

Among patients presenting directly to a thrombectomy-equipped center with a large-vessel ischemic stroke, going directly to the endovascular suite and forgoing initial IV thrombolytic therapy provides ...

Please provide your email address to receive an email when new articles are posted on . Reteplase was superior to alteplase at reducing disability after acute ischemic stroke. Mortality was similar ...

Medical staff have increased the use of tPA or "clot busting therapy" for ischemic stroke by 13.5 times throughout University Hospitals system hospitals since implementing the System Stroke Program ...

Until recently, i.v. alteplase was only recommended for use within 3 hours of symptom onset of AIS. [2–4] However, the results of two large clinical trials published in 2008 clearly demonstrated the ...